{
    "2019-11-11": [
        [
            {
                "time": "2018-03-15",
                "original_text": "The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Novo Nordisk",
                        "Allergan",
                        "Sanofi",
                        "Novartis",
                        "J&J"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Approval",
                        "Imbruvica",
                        "Rituxan",
                        "First-Line CLL"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}